MRC1 and cancer: However, in spite of the higher mutational load and the consequent higher immune response to cancer cells and high responsiveness toward immune checkpoint blockade, a full explanation for the better outcome of MMR-deficient CRC is still lacking (Ozcan et al., 2018).